Alongside Shire, which focuses on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases, in the consortium was venture capital firm Advent Healthcare Ventures, which led the round.
Prexa Pharmaceuticals, a US-based developer of therapies for the human central nervous system, has raised $7m in its series B round from a consortium including drug maker Shire Pharmaceuticals.
Alongside Shire, which focuses on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases, in the consortium was venture capital firm Advent Healthcare Ventures, which led the round. Advent founded Prexa in 2006, and invested $3.1m in it’s A round.
Charles Cohen, partner at Advent and…
